Basilea Pharmaceutica

Basilea Pharmaceutica Celebrates Milestone Payment as Cresemba® Sales Soar in Asia Pacific and China

(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN) announced a significant milestone with a USD 1.25 million payment triggered by the…

2 months ago

Basilea Pharmaceutica Acquires Novel Antibiotics Program Targeting Multidrug-Resistant Gram-Negative Bacteria

(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN), a biopharmaceutical company specializing in severe bacterial and fungal infection treatments, has announced…

4 months ago

Basilea Pharmaceutica Reports Strong H1 2023 Financial Results and Increases Full-Year Guidance

(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company specializing in severe bacterial and fungal infection treatments, has announced robust financial…

9 months ago

Basilea Pharmaceutica Ltd secures non-dilutive refinancing from funds managed by Athyrium Capital Management, LP for its outstanding 2022 convertible bonds

Ad hoc announcement pursuant to Art. 53 LR (PRESS RELEASE) BASEL/ ALLSCHWIL, 7-Sep-2022 — /EuropaWire/ — Basilea Pharmaceutica Ltd (SWX:…

2 years ago

Basilea Pharmaceutica Ltd obtient un refinancement non dilutif auprès de fonds gérés par Athyrium Capital Management, LP pour ses obligations convertibles 2022 en circulation

Annonce ad hoc conformément à l'art. 53LR (COMMUNIQUÉ DE PRESSE) BASEL/ ALLSCHWIL, 7-Sep-2022 — /EuropaWire/ — Basilea Pharmaceutica Ltd (SWX :…

2 years ago

Adesh Kaul will join Basilea Pharmaceutica’s Management Committee as Chief Corporate Development Officer

BASEL, 05-Mar-2018 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Adesh Kaul will join Basilea's Management Committee as…

6 years ago

Basilea Pharmaceutica updates on clinical phase 1/2a program with its anticancer drug candidate BAL101553 at American Society of Clinical Oncology (ASCO)

BASEL, 09-Jun-2017 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that updates were presented on the ongoing clinical phase…

7 years ago

U.S. FDA designated Basilea Pharmaceutica’s isavuconazole as Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis

Basel, Switzerland, 11-12-2013 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated…

10 years ago